blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2619577

EP2619577 - BIOMARKERS OF RENAL INJURY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.06.2018
Database last updated on 11.05.2024
FormerThe patent has been granted
Status updated on  14.07.2017
FormerGrant of patent is intended
Status updated on  28.02.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
University of Pittsburgh - Of the Commonwealth System of Higher Education
200 Gardner Steel Conference Center
Thackeray & O'Hara Streets
Pittsburgh, PA 15260 / US
[2017/33]
Former [2013/31]For all designated states
University of Pittsburgh of the Commonwealth System of Higher Education
200 Gardner Steel Conference Center Thackeray & O'Hara Streets
Pittsburgh, PA 15260 / US
Inventor(s)01 / SINGBARTL, Kai
413 S. Highland Avenue Apt. 2
Pittsburgh, PA 15206 / US
02 / KELLUM, John, A.
5541 Hampton Street
Pittsburgh, PA 15206 / US
 [2013/31]
Representative(s)McNab, Donald C., et al
Marks & Clerk LLP
40 Torphichen Street
Edinburgh EH3 8JB / GB
[N/P]
Former [2013/42]McNab, Donald C., et al
Marks & Clerk LLP
Atholl Exchange
6 Canning Street
Edinburgh EH3 8EG / GB
Former [2013/31]McNab, Donald C.
Marks & Clerk LLP
Aurora
120 Bothwell Street
Glasgow
G2 7JS / GB
Application number, filing date11827278.019.09.2011
[2017/33]
WO2011US52082
Priority number, dateUS20111323500516.09.2011         Original published format: US201113235005
US20100386230P24.09.2010         Original published format: US 386230 P
[2013/31]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012040073
Date:29.03.2012
Language:EN
[2012/13]
Type: A2 Application without search report 
No.:EP2619577
Date:31.07.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 29.03.2012 takes the place of the publication of the European patent application.
[2013/31]
Type: B1 Patent specification 
No.:EP2619577
Date:16.08.2017
Language:EN
[2017/33]
Search report(s)International search report - published on:KR14.06.2012
(Supplementary) European search report - dispatched on:EP31.03.2014
ClassificationIPC:G01N33/50, G01N33/68
[2013/31]
CPC:
G01N33/6893 (EP,US); G01N33/68 (KR); G01N33/50 (KR);
G01N2333/495 (EP,US); G01N2333/70578 (EP,US); G01N2400/40 (EP,US);
G01N2800/347 (EP,US); G01N2800/50 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/31]
Extension statesBA23.04.2013
ME23.04.2013
TitleGerman:BIOMARKER FÜR NIERENLÄSIONEN[2013/31]
English:BIOMARKERS OF RENAL INJURY[2013/31]
French:BIOMARQUEURS DE LÉSION RÉNALE[2013/31]
Entry into regional phase23.04.2013National basic fee paid 
23.04.2013Search fee paid 
23.04.2013Designation fee(s) paid 
23.04.2013Examination fee paid 
Examination procedure23.04.2013Examination requested  [2013/31]
26.08.2014Amendment by applicant (claims and/or description)
10.10.2014Despatch of a communication from the examining division (Time limit: M04)
18.02.2015Reply to a communication from the examining division
16.10.2015Despatch of a communication from the examining division (Time limit: M04)
18.01.2016Reply to a communication from the examining division
01.03.2017Communication of intention to grant the patent
05.07.2017Fee for grant paid
05.07.2017Fee for publishing/printing paid
05.07.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.10.2014
Opposition(s)17.05.2018No opposition filed within time limit [2018/30]
Fees paidRenewal fee
27.09.2013Renewal fee patent year 03
26.09.2014Renewal fee patent year 04
25.09.2015Renewal fee patent year 05
26.09.2016Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.09.2011
AL16.08.2017
AT16.08.2017
CY16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
HR16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
MK16.08.2017
NL16.08.2017
PL16.08.2017
PT16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
TR16.08.2017
IE19.09.2017
LU19.09.2017
MT19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
[2020/33]
Former [2020/30]HU19.09.2011
AT16.08.2017
CY16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
HR16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
MK16.08.2017
NL16.08.2017
PL16.08.2017
PT16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
TR16.08.2017
IE19.09.2017
LU19.09.2017
MT19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2020/27]HU19.09.2011
AT16.08.2017
CY16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
MK16.08.2017
NL16.08.2017
PL16.08.2017
PT16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
TR16.08.2017
IE19.09.2017
LU19.09.2017
MT19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2020/16]HU19.09.2011
AT16.08.2017
CY16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
MK16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
TR16.08.2017
IE19.09.2017
LU19.09.2017
MT19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2019/51]HU19.09.2011
AT16.08.2017
CY16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
MK16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
IE19.09.2017
LU19.09.2017
MT19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2019/46]HU19.09.2011
AT16.08.2017
CY16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
IE19.09.2017
LU19.09.2017
MT19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2019/31]HU19.09.2011
AT16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
IE19.09.2017
LU19.09.2017
MT19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/43]AT16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
IE19.09.2017
LU19.09.2017
MT19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/39]AT16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
IE19.09.2017
LU19.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/34]AT16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SK16.08.2017
SM16.08.2017
IE19.09.2017
LU19.09.2017
CH30.09.2017
LI30.09.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/26]AT16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/24]AT16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
IT16.08.2017
LT16.08.2017
LV16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/23]AT16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
ES16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
NL16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SK16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/21]AT16.08.2017
CZ16.08.2017
DK16.08.2017
ES16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
NL16.08.2017
PL16.08.2017
RS16.08.2017
SE16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/12]AT16.08.2017
ES16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
NL16.08.2017
PL16.08.2017
RS16.08.2017
SE16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/11]AT16.08.2017
ES16.08.2017
FI16.08.2017
LT16.08.2017
NL16.08.2017
PL16.08.2017
RS16.08.2017
SE16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/10]AT16.08.2017
FI16.08.2017
LT16.08.2017
NL16.08.2017
RS16.08.2017
SE16.08.2017
NO16.11.2017
Former [2018/09]FI16.08.2017
LT16.08.2017
NL16.08.2017
SE16.08.2017
NO16.11.2017
Former [2018/08]FI16.08.2017
LT16.08.2017
NL16.08.2017
NO16.11.2017
Former [2018/07]LT16.08.2017
NO16.11.2017
Documents cited:Search[A]WO2010025434  (ASTUTE MEDICAL INC [US], et al) [A] 1-7,12-15;
 [A]WO2010025424  (ASTUTE MEDICAL INC [US], et al) [A] 1-7,12-15;
 [X]WO2010036342  (UNIV PITTSBURGH [US], et al) [X] 1-7,12-15* the whole document *;
 [A]WO2010048347  (ASTUTE MEDICAL INC [US], et al) [A] 1-7,12-15;
 [A]  - S G COCA ET AL, "Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review", KIDNEY INTERNATIONAL, (20071219), vol. 73, no. 9, doi:10.1038/sj.ki.5002729, ISSN 0085-2538, pages 1008 - 1016, XP055027810 [A] 1-7,12-15

DOI:   http://dx.doi.org/10.1038/sj.ki.5002729
 [A]  - PARIKH CHIRAG R ET AL, "New biomarkers of acute kidney injury", CRITICAL CARE MEDICINE, LIPPINCOTT WILLIAMS & WILKINS, US, (20080401), vol. 36, no. 4, suppl, doi:10.1097/CCM.0B013E318168C652, ISSN 1530-0293, pages s159 - s165, XP009108669 [A] 1-7,12-15

DOI:   http://dx.doi.org/10.1097/CCM.0b013e318168c652
International search[A]US2009239242  (KILTY CORMAC GERALD [IE], et al);
 [X]US2010081148  (SINGBARTL KAI [US], et al);
 [Y]  - SRISAWAT, NATTACHAI ET AL., "Recovery from acute kidney injury: determinants and predictors.", CONTRIB NEPHROL., (20100420), vol. 165, pages 284 - 291, XP008168383

DOI:   http://dx.doi.org/10.1159/000313768
 [Y]  - SPURGEON, KIMBERLY R. ET AL., "Transforming growth factor-beta in acute renal failure: receptor expression, effects on proliferation, cellularity, and vascularization after recovery from injury.", AM. J. PHYSIOL RENAL PHYSIOL., (2005), vol. 288, no. 3, pages 568 - 577, XP055109356

DOI:   http://dx.doi.org/10.1152/ajprenal.00330.2004
 [A]  - VENKATARAMAN, RAMESH ET AL., "Defining acute renal failure: the RIFLE criteria.", J. INTENSIVE CARE MED., (200708), vol. 22, no. 4, pages 187 - 193, XP008168384

DOI:   http://dx.doi.org/10.1177/0885066607299510
by applicantUS5480792
 US5525524
 US5571698
 US5631171
 US5679526
 US5824799
 US5851776
 US5885527
 US5922615
 US5939272
 US5947124
 US5955377
 US5985579
 US6019944
 US6057098
 US6113855
 US6143576
 US6350571
 WO2010036342
    - KELLUM, CRIT. CARE MED., (2008), vol. 36, pages 141 - 45
    - RICCI ET AL., KIDNEY INT., (2008), vol. 73, pages 538 - 546
    - MEHTA ET AL., CRIT. CARE, (2007), vol. 11, page R31
    - Current Medical Diagnosis & Treatment, MCGRAW HILL, (2008), pages 785 - 815
    - WILSON ET AL., J. IMMUNOL. METHODS, (1994), vol. 175, pages 267 - 273
    - YARMUSH ET AL., J. BIOCHEM. BIOPHYS. METHODS, (1992), vol. 25, pages 85 - 97
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
    - Harrison's Principles of Internal Medicine, MCGRAW HILL, pages 1741 - 1830
    - Merck Manual
    - PRAUGHT ET AL., CURR OPIN NEPHROL HYPERTENS, (2005), vol. 14, pages 265 - 270
    - CHERTOW ET AL., JAM SOC NEPHROL, (2005), vol. 16, pages 3365 - 3370
    - LASSNIGG ET AL., JAM SOC NEPHROL, (2004), vol. 15, pages 1597 - 1605
    - BELLOMO ET AL., CRIT CARE, (2004), vol. 8, no. 4, pages R204 - 212
    - MCCOLLOUGH ET AL., REV CARDIOVASC MED., (2006), vol. 7, no. 4, pages 177 - 197
    - PECOITS-FILHO ET AL., "Associations between circulating inflammatory markers and residual renal function in CRF patients", AM J KIDNEY DIS., (2003), vol. 41, no. 6, pages 1212 - 1218
    - ALI ET AL., "Incidence and outcomes in acute kidney injury: a comprehensive population-based study", JAM SOC NEPHROL, (2007), vol. 18, pages 1292 - 1298
    - UCHINO ET AL., "Acute renal failure in critically ill patients: a multinational, multicenter study", JAMA, (2005), vol. 294, pages 813 - 818
    - PALEVSKY ET AL., "Intensity of renal support in critically ill patients with acute kidney injury", N ENGL J MED, (2008), vol. 359, pages 7 - 20
    - HANSELL ET AL., "Hyaluronan content in the kidney in different states of body hydration", KIDNEY INT, (2000), vol. 58, pages 2061 - 2068
    - SIBALIC ET AL., "Upregulated renal tubular CD44, hyaluronan, and osteopontin in kdkd mice with interstitial nephritis", NEPHROL DIAL TRANSPLANT, (1997), vol. 12, pages 1344 - 1353
    - LEWINGTON ET AL., "Expression of CD44 in kidney after acute ischemic injury in rats", AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, (2000), vol. 278, pages R247 - 254
    - SANO ET AL., "Localization and roles of CD44, hyaluronic acid and osteopontin in IgA nephropathy", NEPHRON, (2001), vol. 89, pages 416 - 421
    - MELIN ET AL., "Ischemia-induced renal expression of hyaluronan and CD44 in diabetic rats", NEPHRON EXP NEPHROL, (2006), vol. 103, pages E86 - 94
    - YANG ET AL., "Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis", AM J PATHOL, (2001), vol. 159, pages 1465 - 1475
    - OKAJIMA K, "Regulation of inflammatory responses by natural anticoagulants", IMMUNOL REV, (2001), vol. 184, pages 258 - 274
    - LAURENT ET AL., "Hyaluronan", FASEB J, (1992), vol. 6, pages 2397 - 2404
    - DELPECH ET AL., "Hyaluronan: fundamental principles and applications in cancer", J INTERN MED, (1997), vol. 242, pages 41 - 48
    - "The role and regulation of tumor associated hyaluronan", KNUDSON ET AL., The Biology of Hyaluronan, WILEY CHICHISTER (CIBA FOUNDATION SYMPOSIUM 143, (1989), pages 150 - 169
    - SATTAR ET AL., "Does hyaluronan have a role in endothelial cell proliferation of the synovium?", SEMIN ARTHRITIS RHEUM, (1992), vol. 22, pages 37 - 43
    - LOKESHWAR VB; SELZER MG, "Differences in hyaluronic acid mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells", J BIOL CHEM, (2000), vol. 275, pages 27641 - 27649
    - CSOKA TB; FROST GI; STERN R, "Hyaluronidases in tissue invasion", INVASION METASTASIS, (1997), vol. 17, pages 297 - 311
    - "Enzymatic pathways of hyaluronan catabolism", RODEN L; CAMPBELL P; FRASER JR; LAURENT TC; PETROFF H; THOMPSON JN, The Biology of Hyaluronan, WILEY, (1989), pages 60 - 86
    - LOKESHWAR VB; OBEK C; PHAM HT; WEI D; YOUNG MJ; DUNCAN RC, "Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade", J UROL, (2000), vol. 163, pages 348 - 356
    - LOKESHWAR ET AL., "Bladder Tumor Markers for Monitoring Recurrence and Screening Comparison of Hyaluronic Acid-Hyaluronidase and BTA-Stat Tests", CANCER, (2002), vol. 95, pages 61 - 72
    - WEST ET AL., "Angiogenesis induced by degradation products of hyaluronic acid", SCIENCE, (1985), vol. 228, pages 1324 - 1326
    - "Enzymatic pathways of hyaluronan catabolism", RODEN ET AL., The Biology of hyaluronan, WILEY CHICHISTER (CIBA FOUNDATION SYMPOSIUM 143, (1989), pages 60 - 86
    - WEST ET AL., "Gold, Purification and properties of hyaluronidase from human liver", BIOCHEM. J., (1982), vol. 205, pages 69 - 74
    - "Turnover and metabolism of Hyaluronan", FRASER; LAURENT, Biology of Hyaluronan, WILEY CHICHISTER (CIBA FOUNDATION SYMPOSIUM 143, (1989), pages 41 - 59
    - ZHU ET AL., "Molecular cloning of a mammalian hyaluronidase reveals identity with hemopexin, a serum heme-binding protein", J. BIOL. CHEM., (1994), vol. 269, pages 32092 - 32097
    - LIN ET AL., "A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus layer surrounding the egg", J. CELL BIOL., (1995), vol. 125, pages 1157 - 1163
    - MCCORMICK; ZETTER, "Adhesive interactions in angiogenesis and metastasis", PHARMACOL. THER., (1992), vol. 53, pages 239 - 260
    - HOBARTH ET AL., "Topical chemo-prophylaxis of superficial bladder cancer by mitomycin C and adjuvant hyaluronidase", EUR. UROL., (1992), vol. 21, pages 206 - 210
    - "The role and regulation of tumor-associated hyaluronan", KNUDSON ET AL., The Biology of Hyaluronan, WILEY, CHICHESTER (CIBA FOUNDATION SYMPOSIUM 143, (1989), pages 150 - 169
    - LIN ET AL., "Urinary hyaluronic acid is a Wilms' tumor marker", J. PED. SURG., (1995), vol. 30, pages 304 - 308
    - STERN ET AL., "Hyaluronidase levels in urine from Wilms' tumor patients", J. NATL. CANC. INST., (1991), vol. 83, pages 1569 - 1574
    - WANG ET AL., "Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma", BIOCHEM BIOPHYS RES COMMUN, (2009), vol. 380, pages 286 - 291
    - TAKEDA ET AL., "Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease", PROC NATL ACAD SCI USA, (2008), vol. 105, pages 10895 - 10900
    - SHETTY ET AL., "Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkB activation in epithelial cell lines", APOPTOSIS, (2002), vol. 7, pages 413 - 420
    - WOLF G., "Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway", KIDNEY INT, (2006), vol. 70, pages 1914 - 1919
    - SAKURAI ET AL., "An in vitro tubulogenesis system using cell lines derived from the embryonic kidney shows dependence on multiple soluble growth factors", PROC NATL ACAD SCI USA, (1997), vol. 94, pages 6279 - 6284
    - FOSANG ET AL., MATRIX, (1990), vol. 10, pages 306 - 313
    - TENGBLAD, BIOCHIM. BIOPHYS. ACTA, (1979), vol. 578, pages 281 - 289
    - BITTER; MUIR, "A modified uronic acid carbazole reaction", ANAL. BIOCHEM., (1962), vol. 4, pages 330 - 334
    - DYGERT ET AL., "Determination of reducing sugars with improved precision", ANAL. BIOCHEM., (1965), vol. 13, pages 367 - 374
    - LOKESHWAR ET AL., "Ankyrin binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function", J. CELL BIOL., (1994), vol. 126, pages 1099 - 1109
    - FISCHER ET AL., INTENSIVE CARE MED., (2003), vol. 29, pages 1043 - 1051
    - BAGSHAW ET AL., NEPHROL. DIAL. TRANSPLANT, (2008), vol. 23, pages 1203 - 1210
    - VAN ERP ET AL., J. IMMUNOASSAY, (1991), vol. 12, pages 425 - 443
    - NELSON ET AL., COMPUT. METHODS PROGRAMS BIOMED., (1988), vol. 27, pages 65 - 68
    - CWIRLA ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 6378 - 6382
    - DEVLIN ET AL., SCIENCE, (1990), vol. 249, pages 404 - 406
    - SCOTT ET AL., SCIENCE, (1990), vol. 249, pages 386 - 388
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.